iCAD, Inc. (NASDAQ:ICAD) Holdings Raised by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in iCAD, Inc. (NASDAQ:ICAD) by 6.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 276,493 shares of the technology company’s stock after purchasing an additional 17,059 shares during the quarter. Geode Capital Management LLC owned approximately 1.04% of iCAD worth $506,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of ICAD. waypoint wealth counsel raised its holdings in shares of iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after acquiring an additional 4,400 shares during the period. Thompson Davis & CO. Inc. acquired a new stake in iCAD during the 4th quarter valued at $31,000. PKS Advisory Services LLC purchased a new stake in shares of iCAD in the fourth quarter valued at $53,000. Summit Trail Advisors LLC purchased a new position in shares of iCAD during the fourth quarter valued at $214,000. Finally, First Eagle Investment Management LLC raised its position in iCAD by 6.1% during the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company’s stock valued at $1,311,000 after buying an additional 41,000 shares during the period. Institutional investors and hedge funds own 24.61% of the company’s stock.

iCAD Stock Up 2.3 %

Shares of ICAD stock opened at $3.50 on Friday. iCAD, Inc. has a 12 month low of $1.18 and a 12 month high of $3.78. The company has a market cap of $95.78 million, a PE ratio of -26.92 and a beta of 1.78. The business’s 50 day moving average is $2.40 and its two-hundred day moving average is $2.26.

iCAD (NASDAQ:ICAD) last posted its quarterly earnings data on Wednesday, March 19th. The technology company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%. The business had revenue of $5.41 million for the quarter, compared to analyst estimates of $4.72 million.

Wall Street Analysts Forecast Growth

ICAD has been the topic of a number of research reports. Laidlaw reiterated a “hold” rating on shares of iCAD in a report on Thursday, April 17th. Craig Hallum downgraded iCAD from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 16th. BTIG Research downgraded iCAD from a “buy” rating to a “neutral” rating in a report on Wednesday, April 16th. Finally, StockNews.com began coverage on shares of iCAD in a research note on Saturday, April 26th. They issued a “sell” rating for the company.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.